Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  dalteparin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-12 of 12 for your search:
Start Over
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FRAG-A001-401, NCT00942968
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients
Phase: Phase IV
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0487, NCI-2011-01773, NCT00966277
Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066775, NCCTG-979251, NCI-P98-0139, NCT00003674
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068075, P30CA016042, UCLA-9910055, P-UPJOHN-98-FRAG-076, NCI-G00-1822, NCT00006083
Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 524E-CVD-0056-013, NCT00135876
A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 25387, 1 R01 HL95109-01, NCT00876915
Fragmin in Ovarian Cancer: Utility on Survival (FOCUS)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: NRA6300011-FOCUS-II, NCT00239980
Phase II Randomized Study of Gemcitabine Hydrochloride With Versus Without Dalteparin in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Unknown
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: PRH-HCTU-FRAGEM, PRH-HCTU-FRAGEM-V-12.1, CTA-MF8000/13558, EU-20721, LILLY-PRH-HCTU-FRAGEM, FRAGEM, ISRCTN76464767, NCT00462852
Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000069119, E1F01, ECOG-E1F01, NCT00028678
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 16M-11-1, NCI-2011-03784, NCT01518465
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic or Unresectable Kidney Cancer
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: I 145508, NCI-2009-01694, NCT01061411
DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study
Phase: No phase specified
Type: Supportive care
Status: Closed
Age: 30 and over
Sponsor: Other
Protocol IDs: 2004-0743, NCI-2010-00755, NCT00525057
Start Over